X

 
News

BeiGene News

See all News

  • March 5, 2021
    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer

    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer

    Read More
  • March 2, 2021
    Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

    Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

    Read More
  • February 26, 2021
    BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan

    BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan

    Read More
  • February 25, 2021
    BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results

    BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results

    Read More
  • February 17, 2021
    Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

    Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

    Read More
  • February 17, 2021
    BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia

    BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia

    Read More
  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160    Listings
  • 8Internally Developed
    Clinical Candidates
  • 6Marketed
    Products
    in China
  • 1Approved
    Product
    in the U.S.
  • 5400+Global Team
story
 
BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.

2010

  • BeiGene was founded as a research and development company
BeiGene R&D Center

2011

  • Established the first R&D center in Beijing
  • Initiated PARP and RAF discovery programs
Immuno-oncology Therapies

2012

  • Initiated PD-1 and BTK discovery programs 
Clinical development in Australia

2013

  • Began clinical development of lifirafenib in Australia
Clinical Researcher

2014

  • Began clinical development of pamiparib and zanubrutinib in Australia
BeiGene opens first US office

2015

  • Began clinical development in China
  • Expanded into the U.S. with the first office established in Cambridge, MA
First China biotech to go public on the Nasdaq

2016

  • Became the first biotech to go public on Nasdaq in 2016 after a months-long offering freeze with a $182 million IPO
Collaboration with Celgene

2017

  • Initiated the first global Phase 3 registrational trial of zanubrutinib
  • Entered a global strategic immuno-oncology collaboration with Celgene (now Bristol Myers Squibb) on tislelizumab
  • Transformed into a commercial-stage company by absorbing Celgene’s commercial operation in China
  • Completed construction of the Suzhou multi-functional manufacturing facility
BeiGene expands global operations

2018

  • Completed dual primary listing on Hong Kong Stock Exchange with a $902 million IPO
  • Expanded into Europe with opening of the Basel office
  • Secured national reimbursement in China for both Revlimid® and Vidaza®*
Established research institute

2019

  • Received the first FDA approval for BRUKINSA® (zanubrutinib)
  • Received the first approval for tislelizumab in China
  • Entered a global strategic oncology collaboration with Amgen
  • Completed the first plant of the Guangzhou biologics manufacturing facility
  • Established BeiGene Suzhou Research Institute
Clinical development

2020

  • Received the first approvals for BRUKINSA® in China
  • Received the second approval for tislelizumab in China
  • Completed a registered direct offering of approx. $2.07 billion
  • Secured national reimbursement in China for tislelizumab, BRUKINSA®, and XGEVA®**
  • Established the Shanghai R&D center
third approval for tislelizumab

2021

  • Entered a global strategic collaboration with Novartis
  • Received the third approval for tislelizumab in China

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeagen_LogoAmbrx LogoMirati LogoMEI logoAmgen logoEUSA LogoAssembly Bio LogoChi-Med LogoBio-Thera LogoSinglomics LogostandtxBITT LogoNovartis

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers